UK markets close in 3 hours 57 minutes
  • FTSE 100

    7,489.57
    +1.42 (+0.02%)
     
  • FTSE 250

    19,960.42
    +48.02 (+0.24%)
     
  • AIM

    911.29
    -3.46 (-0.38%)
     
  • GBP/EUR

    1.1810
    -0.0009 (-0.08%)
     
  • GBP/USD

    1.2098
    +0.0022 (+0.18%)
     
  • BTC-GBP

    19,156.06
    -258.46 (-1.33%)
     
  • CMC Crypto 200

    539.20
    -18.15 (-3.26%)
     
  • S&P 500

    4,122.47
    -17.59 (-0.42%)
     
  • DOW

    32,774.41
    -58.13 (-0.18%)
     
  • CRUDE OIL

    88.88
    -1.62 (-1.79%)
     
  • GOLD FUTURES

    1,805.60
    -6.70 (-0.37%)
     
  • NIKKEI 225

    27,819.33
    -180.63 (-0.65%)
     
  • HANG SENG

    19,610.84
    -392.60 (-1.96%)
     
  • DAX

    13,548.93
    +13.96 (+0.10%)
     
  • CAC 40

    6,481.39
    -8.61 (-0.13%)
     

Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?

·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Roche (OTC: RHHBY) is considering a launch of its Alzheimer's disease drug, gantenerumab, at a price that could undercut competition from Biogen's (NASDAQ: BIIB) Aduhelm. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss reasons why Biogen investors should be concerned if Roche's drug gains FDA approval.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting